RNA interference (RNAi), sometimes called gene silencing, is an approach to therapeutics in certain diseases that are caused by the production of abnormal proteins or an overproduction of proteins, which can be treated by turning off or silencing the gene. One of the companies working on the cutting edge of this field is Pasadena, California-based Arrowhead Pharmaceuticals, which is expecting 2020 to be a real inflection point.